Altimmune Inc (ALT)
6.23
+0.08
(+1.30%)
USD |
NASDAQ |
Oct 04, 16:00
6.22
-0.01
(-0.16%)
After-Hours: 20:00
Altimmune Shareholders Equity (Annual): 194.10M for Dec. 31, 2023
Shareholders Equity (Annual) Chart
Historical Shareholders Equity (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 194.10M |
| December 31, 2022 | 185.29M |
| December 31, 2021 | 199.14M |
| December 31, 2020 | 225.88M |
| December 31, 2019 | 45.52M |
| December 31, 2018 | 48.31M |
| December 31, 2017 | 48.68M |
| December 31, 2016 | 32.21M |
| December 31, 2015 | 16.65M |
| December 31, 2014 | 18.27M |
| Date | Value |
|---|---|
| December 31, 2013 | 7.336M |
| December 31, 2012 | 11.67M |
| December 31, 2011 | 15.85M |
| December 31, 2010 | 12.21M |
| December 31, 2009 | 3.152M |
| December 31, 2008 | 18.96M |
| December 31, 2007 | 40.57M |
| December 31, 2006 | -4.396M |
| December 31, 2005 | 56.10M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Annual) Range, Past 5 Years
45.52M
Minimum
2019
225.88M
Maximum
2020
169.98M
Average
194.10M
Median
2023
Shareholders Equity (Annual) Benchmarks
| Eli Lilly and Co | 10.77B |
| Amgen Inc | 6.232B |
| Pfizer Inc | 89.01B |
| Avid Bioservices Inc | 60.89M |
| Regeneron Pharmaceuticals Inc | 25.97B |